Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hematopoietic malignancies and gene therapy].

Keiya Ozawa1

  • 1Division of Hematology, Dept. of Medicine, Jichi Medical School.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 2, 2003
PubMed
Summary

Gene therapy for blood cancers faces challenges. Suicide gene therapy offers a way to control side effects, but safety concerns like insertional mutagenesis require further study for stem cell gene therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Soluble PD-L1-secreting umbilical cord-derived mesenchymal stromal cells transiently attenuate established xenogeneic T cell activation in vivo.

Scientific reports·2026
Same author

Trichostatin A Sensitizes Tumor Cells to Apoptosis Induced by Soluble Trimeric TRAIL-Expressing Human Mesenchymal Stromal Cells.

Cancer science·2025
Same author

Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia.

Blood advances·2025
Same author

Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study.

British journal of haematology·2025
Same author

Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials.

Annals of hematology·2025
Same author

BCMA-CAR Therapy for Multiple Myeloma in NOG Mice Prevents the Progression of Anemia and Bone Lesions.

Human gene therapy·2025

Area of Science:

  • Hematology
  • Oncology
  • Immunology
  • Gene Therapy

Context:

  • Direct gene therapy for widespread hematopoietic malignancies is challenging.
  • Indirect approaches like immuno-gene-therapy, specifically suicide gene therapy, are explored for managing side effects such as graft-versus-host disease (GVHD) after bone marrow transplantation.
  • The HSV-TK gene is commonly used as a suicide gene in these strategies.

Purpose:

  • To investigate the efficacy of suicide gene therapy in eliminating donor lymphocytes to mitigate severe side effects like GVHD.
  • To explore the potential of anti-tumor-angiogenesis therapy for hematological malignancies.
  • To address safety concerns in hematopoietic stem cell gene therapy, particularly regarding insertional mutagenesis.

Summary:

  • Suicide gene therapy, using genes like HSV-TK, is investigated as an indirect approach for hematopoietic malignancies to control donor lymphocyte activity and prevent GVHD.
  • Basic research is examining anti-tumor-angiogenesis therapy for blood cancers.
  • Leukemia development in two patients undergoing hematopoietic stem cell gene therapy, linked to LMO2 gene activation via insertional mutagenesis from retroviral vectors, highlights critical safety issues.

Impact:

  • Highlights the potential of suicide gene therapy in managing complications of bone marrow transplantation for leukemia.
  • Identifies anti-tumor-angiogenesis as an area for further research in hematological oncology.
  • Underscores the urgent need for enhanced safety protocols and further research into insertional mutagenesis risks associated with retroviral vector-mediated stem cell gene therapy to prevent secondary malignancies.

Related Experiment Videos